drugset

drugset / Trial / NCT04781140

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD

NCT04781140 ↗

Phase 4 Recruiting 286 enrolled Supernus Pharmaceuticals, Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.

Timeline

Start: 2024-03-19
Primary completion: 2026-06
Completion: 2026-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Viloxazine	Small molecule	100 mg	—

Indications